About this episode

Rob interviews Jake Leach, the new CEO of Dexcom, discussing advancements in diabetes technology and challenges faced by the company.

Rob was at ADA 2026 in spirit — armed with press access and a list of questions unrelated to the usual conference talking points. His first guest from that coverage is Jake Leach, Dexcom's new CEO, who took over the role on January 1st after 22 years at the company. This is Jake's first time on Diabetics Doing Things as CEO. It sounds like two people having a real conversation about what it means to lead a company that millions of people with diabetes depend on every single day. They get into the research that came out of this year's scientific sessions — specifically, the CONNECT trial, a global randomized controlled study that examined what happens when people with type 2 diabetes who aren't using insulin start using the Dexcom G7. The numbers are striking: an average 1.6% reduction in HbA1C, 5 additional hours per day in range, and 97% sensor utilization over 6 months. That last number might be the most telling — it answers the question the diabetes world has been asking for years about whether people without hypoglycemia risk would actually wear a CGM consistently. Turns out, they will. Rob also pushes the conversation into territory that most executive interviews don't…

People in this episode

Host: Rob

Guest: Jake Leach

Topics covered

• diabetes technology
• CGM
• healthcare leadership
• clinical trials
• patient experience

Keywords

• Dexcom
• G7
• diabetes
• HbA1C
• CONNECT trial
• CGM
• healthcare

Mentioned in this episode

Organizations: Dexcom, ADA

Products: Dexcom G7

More episodes of Diabetics Doing Things Podcast

• Episode 360 - Highs, Lows, and Hormones: Aging with Type 1 Diabetes with Melissa Slemp · July 8, 2026
• Episode 358 - Travel, Diabetes, and Disrupting What You Think You Know with Dylan Leonard · June 17, 2026

Explore listener stats, chart rankings, contacts and more on the Diabetics Doing Things Podcast podcast page.